{"id":"clonazepam-and-paroxetine","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Sedation/drowsiness"},{"rate":"15-25","effect":"Dizziness"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Tremor"},{"rate":null,"effect":"Dependence/withdrawal risk (clonazepam)"},{"rate":"10-20","effect":"Sexual dysfunction (paroxetine)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clonazepam is a benzodiazepine that potentiates GABA-A receptor activity, increasing chloride influx and neuronal hyperpolarization to produce anxiolytic and sedative effects. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter, increasing synaptic serotonin availability to improve mood and reduce anxiety. This combination targets both GABAergic and serotonergic systems for synergistic anxiolytic and antidepressant effects.","oneSentence":"Clonazepam enhances inhibitory GABA signaling in the central nervous system while paroxetine inhibits serotonin reuptake, together reducing anxiety and depressive symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:34.722Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anxiety disorders"},{"name":"Panic disorder"},{"name":"Major depressive disorder with anxiety"},{"name":"Obsessive-compulsive disorder"}]},"trialDetails":[{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT02852577","phase":"PHASE4","title":"Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine","status":"COMPLETED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2000-01","conditions":"Panic Disorder, Agoraphobia","enrollment":120},{"nctId":"NCT00031317","phase":"PHASE4","title":"Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2002-02","conditions":"Panic Disorder","enrollment":60},{"nctId":"NCT00025740","phase":"PHASE4","title":"Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2001-10","conditions":"Post Traumatic Stress Disorder","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"clonazepam and paroxetine","genericName":"clonazepam and paroxetine","companyName":"National Institute of Mental Health (NIMH)","companyId":"national-institute-of-mental-health-nimh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clonazepam enhances inhibitory GABA signaling in the central nervous system while paroxetine inhibits serotonin reuptake, together reducing anxiety and depressive symptoms. Used for Anxiety disorders, Panic disorder, Major depressive disorder with anxiety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}